Table 2.
Chemo-IGRT for locally advanced NSCLC.
| Reference | RT technique | Dose | Clinical outcome | Toxicity |
|---|---|---|---|---|
| Bral et al. (75) | HT | PTV 70.5 Gy/30 fractions | MS: Stage IIIA vs. III B (21 vs. 12 months, p = 0.03). 2-year LPFS: 50% | Late lung toxicity Grade 2 23% Grade 3 16% Two deaths due to grade 5 RP |
| Song et al. (76) | SIB with HT | GTV: 60–70.4 Gy (2–2.4 Gy/fraction) PTV: 50–64 Gy (1.8–2 Gy/fraction) | Stage III 2 year LC 62% (78% with C-Ch) MS not reached 2 year OS 59% (75% with C-Ch) Only 1 in-field failure was observed | Acute: 14% with grade 3 esophagitis Late: 11% with grade 5 treatment related pneumonitis V5 of contralateral lung is a significant predictor of severe RP (p = 0.029) |
| Osti et al. (77) | 3D-CRT under kV CBCT image guidance | PTV 60 Gy/20 fractions | Local failure: 37% MS (stage III): 13 months | No patient with >grade 3 treatment related toxicities |
| Bearz et al. (78) | HT | 60 Gy/25 fractions | ORR: 84% MS: 24 monthsa | No RP reported No >grade 3 esophagitis |
| Donato et al. (79) | HT | 67.5–68.4 Gy/30 fractions | Progression in 26% MS 24.1 months (C-Ch) | Acute grade 3 RP 10% Late grade 3 RP 5% No >grade 3 toxicity observed |
a Induction + concurrent chemotherapy; SIB, simultaneously integrated boost; HT, helical tomotherapy; 3D-CRT, 3D conformal radiotherapy; C-Ch, concurrent chemotherapy; LC, local control; OS, overall survival; MS, median survival; LPFS, local progression free survival; RP, radiation pneumonitis.